

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Sex has no detectable net benefits for

Candida albicans

A thesis presented in partial fulfillment of the requirements for the
degree of

Doctor of Philosophy

In

Molecular Microbiology

at Massey University, Palmerston North

New Zealand

Ningxin Zhang

2012

ABSTRACT

Like many other important opportunistic human fungal pathogens, for more than a century *Candida albicans* was thought to be strictly asexual until a parasexual cycle was recently discovered in the laboratory. It is uncertain, however, whether sex is still a viable reproductive strategy for *C. albicans*. In this study I tested whether or not mating enhanced survival of parental genes in this yeast, by mating 10 clinical isolates and testing recombinants' fitness.

Clinical isolates of *C. albicans* usually are diploid, carrying both the *MTL α* and *MTL α* mating type alleles, each on a different copy of chromosome 5. These strains are apparently incapable of meiosis and cannot mate with each other, because the α 1- α 2 heterodimer suppresses mating. Through selection on sorbose-containing agar I induced loss of *MTL*-heterozygosity and generated 5 *MTL α* and 5 *MTL α* derivatives of clinical isolates. Existing mating techniques involve the use of auxotrophic markers, requiring time-consuming sequential disruption of two copies of biosynthetic genes if wild-type clinical isolates are to be mated. Furthermore, auxotrophy affects the virulence of a strain, and this can potentially interfere with comparing the fitness of recombinants with that of their parents. I therefore developed a method for mating clinical isolates marked with two drug resistance markers, the mycophenolic acid (MPA) resistance-conferring allele of *IMH3* and the nourseothricin (NAT) resistance gene *CaNAT1*, allowing selection of recombinants on the basis of resistance to both agents. I marked all *MTL α* strains

with the MPA resistance gene and all *MTL* α strains with the NAT resistance gene. This allowed 25 combinations for mating. Recombinants were obtained from 15 combinations of 9 strains. It was found that not all *C. albicans* clinical isolates could mate.

Using growth rate as the criterion, I tested the fitness of clinical isolates, *MTL*-homozygous derivatives with and without resistance markers and recombinants during adaptation to a novel environment (YPD medium), maximizing the potential benefits of sex. After computationally correcting for the impact of experimental manipulations, I calculated the net benefit of sex as the difference in the number of offspring from two cells that become mating competent and engage in sex compared to the offspring they could have produced by continued clonal reproduction. My results indicated that, as a rule, engaging in sex reduces the chances of survival of *C. albicans*' genes, in part because *MTL* homozygosis significantly reduced growth rates. Through fitness increase after recombination, sex may eventually confer a net benefit for some strain combinations in the laboratory, but this probably occurs too late to prevent elimination of recombinants by competition and genetic drift in nature. Sex in *C. albicans* therefore diminished parents' chances to pass on their genes to future generations. These findings have a significant impact on the assessment of the role of sex in *C. albicans* and other "asexual" human fungal pathogens. Recent loss of the function of sex and incomplete decay of the sex machinery are the most likely explanation of *C. albicans*'s residual ability to mate, and one that also needs to be considered in other fungal pathogens.

ACKNOWLEDGEMENTS

First and foremost, I would like to express my deep and sincere gratitude to my supervisor Dr. Jan Schmid for his enthusiastic supervision during this work. His ideas and tremendous support had a major influence on this thesis. His immense knowledge and logical way of thinking have been of great value for me. His understanding, encouraging and guidance have helped me a lot in all the time of research and writing of this thesis. I could not have imagined having a better supervisor for my Ph.D study. Also, I am deeply grateful to my co-supervisors, Professor Richard Cannon and Dr. Barbara Holland for their detailed and constructive comments, guidance in statistical analysis and for their important input and support throughout this work. Furthermore, I would like to give special thanks to Ms. Bebe Magee and Dr. Pete Magee for their help on solving different problems through this study and for providing me several useful technical protocols, and for the great collaboration over the years. It was a pleasure to talk with them and to benefit from their knowledge. Especially, I enjoyed very much the interesting and fruitful discussions through these years.

I would like to thank Dr. Fran Wolber for assistance with FACS analysis, Dmitry Sokolov for helping with the microscopic experiments and Richard Bennett for providing *MTL* homozygous clinical isolates.

I would like to thank all my colleagues for the great time I had in our Institute and our lab. I enjoyed the atmosphere, their friendship, and their support. I am grateful

to the Institute secretaries Ann Truter and Cynthia Cressell for their help for printing the thesis. My thanks to my former labmates Shuguang Zhang, Yeying Wang, Zhuo Zhou, Synodalia Wattimena, and Panimalar Vijayan for their help, cooperation and all the fun times we had. Many thanks to Dr. Yu Cao, whose support gave me strength during the final phase of thesis preparation. Also I thank all my Chinese friends for their friendship and encouragements: Fuguang Cao, Jiayi Lu, Song Shi, Amy Yu, Xiangqian Zhu, Yanli Zhang, Qiong Zhao, Peter Zhang, Anna Chen, Daniel Lai and Qiong Lai.

Lastly, and most importantly, I wish to thank my parents and Tim and Julie for their understanding, endless patience and encouragement when it was most required. To them I dedicate this thesis.

This research was founded through Marsden Grant (MAU603) by the Royal Society of New Zealand. Their support is gratefully acknowledged.

TABLE OF CONTENTS

ABSTRACT	I
ACKNOWLEDGEMENTS	III
TABLE OF CONTENTS	V
LIST OF FIGURES	X
LIST OF TABLES	XIV
ABBREVIATIONS	XV
1.0. INTRODUCTION	1
1.1. <i>CANDIDA ALBICANS</i> : THE PREDOMINANT PATHOGENIC FUNGUS OF HUMANS:..	2
1.1.1. <i>Fungal pathogens of humans</i>	2
1.1.2. <i>C. albicans: the major fungal pathogen</i>	3
1.1.3. <i>GPG strains are the most successful strains within the species Candida albicans</i>	7
1.2. THE ROLE OF SEX IN THE PATHOGENESIS OF FUNGAL INFECTIONS:	10
1.2.1. <i>Sex in Fungi</i>	10
1.2.2. <i>Sex and virulence in human fungal pathogens</i>	13
1.2.2.1. Many “asexual” human fungal pathogens retain their sexual machinery.....	13
1.2.2.2. Population genetic studies reveal some evidence of recombination in many human fungal pathogens.....	16
1.3. SEX IN <i>C. ALBICANS</i> :.....	18
1.3.1. <i>C. albicans was thought to be asexual</i>	18
1.3.2. <i>Discovery of the mating type locus in Candida albicans</i>	19
1.3.3. <i>C. albicans can mate in the laboratory</i>	23
1.3.4. <i>Mating between clinical isolates</i>	27
1.3.5. <i>Mating between clinical isolates is restricted in nature</i>	29
1.3.6. <i>Population genetic studies reveal evidence of sex -but not much</i>	31
1.4. SELECTION MARKERS FOR ASSESSING THE ABILITY OF CLINICAL ISOLATES TO MATE WITH EACH OTHER	33
1.4.1. <i>Auxotrophic markers</i>	33
1.4.2. <i>Dominant selectable markers</i>	34
1.5 ASSESSMENTS OF THE BENEFIT OF SEX IN THE LABORATORY	36
1.5.1 <i>Sex is expected to be more beneficial if adaptation to a novel environment is required</i>	37
1.6. SUMMARY	38
1.7. AIMS OF THE RESEARCH.....	39
2.0. MATERIALS AND METHODS	41
2.1. BIOLOGICAL MATERIALS.....	42
2.1.1. <i>Candida albicans strains</i>	42

2.1.2. <i>Escherichia coli</i> strains.....	45
2.2. SOURCES OF MATERIALS AND EQUIPMENTS.....	46
2.3. PLASMIDS USED IN THIS STUDY	49
2.4. PLASMIDS DEVELOPED DURING THIS STUDY	50
2.5. MEDIA AND SOLUTIONS	51
2.5.1. <i>Yeast media</i>	51
2.5.1.1. Yeast Extract Peptone Dextrose (YPD).....	51
2.5.1.2. Minimal medium (MM).....	51
2.5.1.3. Sorbose medium	51
2.5.1.4. Spider medium.....	52
2.5.1.5. MPA plates.....	52
2.5.1.6. NAT plates.....	52
2.5.1.7. Phloxine B plates	53
2.5.2. <i>Bacterial media</i>	53
2.5.2.1. Luria-Bertani medium (LB).....	53
2.5.3. <i>General buffers and stock solutions</i>	53
2.6. PRIMERS USED IN THIS STUDY	56
2.7. MICROBIAL GROWTH CONDITIONS.....	58
2.7.1. <i>Storage, growth and manipulation of C. albicans cultures</i>	58
2.7.1.1. Glycerol stocks for <i>Candida albicans</i>	58
2.7.1.2. Drug susceptibility assay for clinical isolates.....	58
2.7.1.3. Sorbose selection of <i>MTL</i> -homozygous derivatives	59
2.7.1.4. Selection of spontaneously arising <i>MTL</i> -homozygotes	60
2.7.1.5. Serial transfer conditions.....	60
2.7.1.6. Growth rate determination.....	61
2.7.1.7. Replica plating	63
2.7.2. <i>Growth conditions for Escherichia coli</i>	63
2.8. DNA MANIPULATION	64
2.8.1. <i>Plasmid DNA isolation</i>	64
2.8.2. <i>C. albicans</i> genomic DNA isolation.....	64
2.8.3. <i>Gel purification of DNA fragments</i>	66
2.8.4. <i>PCR product purification</i>	66
2.8.5. <i>DNA quantification</i>	66
2.8.6. <i>Restriction endonuclease digestion of DNA</i>	67
2.8.7. <i>Calf intestinal alkaline-phosphate (CIAP) treatment of vectors</i>	67
2.8.8. <i>Ligation</i>	67
2.8.9. <i>Creating blunt-ended DNA fragments</i>	68
2.8.10. <i>Agarose gel electrophoresis</i>	68
2.8.11. <i>Polyacrylamide gel electrophoresis (PAGE)</i>	69
2.8.12. <i>Southern blotting</i>	70
2.8.12.1. Probe labeling using Dig-labeling system.....	71
2.8.12.2. Hybridization	71
2.8.13. <i>DNA sequencing</i>	72
2.9. PCR METHODS	72
2.9.1. <i>Routine PCR</i>	72
2.9.2. <i>Colony PCR</i>	73
2.9.3. <i>High-fidelity PCR</i>	73
2.9.4. <i>Recombinant PCR</i>	73
2.9.5. <i>PCR screen for GPG strains</i>	74
2.9.6. <i>Multiplex colony PCR screen for MTL heterozygosity</i>	75

2.10. TRANSFORMATION OF <i>E. COLI</i> AND <i>C. ALBICANS</i>	76
2.10.1. <i>E. coli</i> transformation	76
2.10.1.1. Competent cell preparation.....	76
2.10.1.2. Transformation.....	77
2.10.1.3. Detection of colonies with insert-containing plasmids	77
2.10.2. <i>C. albicans</i> transformation.....	78
2.10.2.1. Heat shock transformation method	78
2.10.2.2. Electroporation method	79
2.11. SELECTION OF MODEL STRAINS	80
2.12. MATING BETWEEN <i>C. ALBICANS</i> STRAINS	81
2.12.1. Mating procedure between clinical isolates.....	81
2.12.2. Selection of mating products using MPA and NAT	82
2.12.3. Mating of clinical isolates with universal mating tester strains.....	82
2.13. MICROSCOPY.....	83
2.13.1. Fluorescence microscopy of DAPI-stained nuclei.....	83
2.14. FLUORESCENCE ACTIVATED CELL SORTING (FACS) ANALYSIS OF DNA CONTENT	84
2.14.1. FACS analysis of recombinants and their parents	84
2.14.2. Calculation of DNA content of recombinants and their parents	85
2.15. STATISTICAL ANALYSIS	86
2.15.1. General statistical analysis	86
2.15.2. Randomization procedure for comparing fitness of parents and recombinants	86
2.16. GROWTH SIMULATIONS.....	87
2.16.1. Simulation of the number of offspring from a single cell, or pairs of cells, engaging in mating relative to the number of offspring from clonally reproducing cells.....	87
2.16.2. Simulation of the number of offspring from pairs of cells losing <i>MTL</i> heterozygosity and engaging in mating relative to the number of offspring from clonally reproducing cells	88
2.16.3. Simulation of the number of offspring from a single cell losing <i>MTL</i> - heterozygosity and engaging in mating, relative to the number of offspring from a clonally reproducing cell.....	90
3.0. SELECTING AND GENERATING PARENT STRAINS FOR MATING	93
3.1. INTRODUCTION.....	94
3.2. MODEL STRAIN SELECTION AND VERIFICATION	96
3.3. MODEL STRAINS WERE ALL SUSCEPTIBLE TO MPA AND NAT	100
3.4. ALL MODEL STRAINS WERE <i>MTL</i> -HETEROZYGOTES.....	100
3.5. SORBOSE SELECTION TO GENERATE <i>MTL</i> HOMOZYGOTES FOR MATING	102
4.0. DEVELOPMENT OF MARKER CASSETTES.....	105
4.1. INTRODUCTION.....	106
4.2. CONSTRUCTION OF A NAT RESISTANCE CASSETTE	109
4.3. CONSTRUCTION OF A MPA RESISTANCE CASSETTE	110
5.0. MARKING OF PARENTAL STRAINS FOR MATING EXPERIMENTS	115
5.1. INTRODUCTION.....	116

5.2. TRANSFORMATION OF <i>MTLα</i> STRAINS WITH THE MPA RESISTANCE CASSETTE	116
5.3. TRANSFORMATION OF <i>MTLα</i> STRAINS WITH THE NAT RESISTANCE CASSETTE	122
5.4. MARKING OF PARENTAL STRAINS WITH BOTH MPA AND NAT RESISTANCE MARKERS	126
5.5. VERIFICATION OF THE POSITION OF THE RESISTANCE CASSETTES BY SOUTHERN BLOT ANALYSIS	126
6.0. DEVELOPMENT OF A NEW MATING PROCEDURE	131
6.1 INTRODUCTION.....	132
6.2. DEVELOPMENT OF A NEW MATING PROCEDURE FOR MARKED CLINICAL ISOLATES	132
7.0. MATING BETWEEN CLINICAL ISOLATES.....	139
7.1 INTRODUCTION.....	140
7.2 MATING COULD OCCUR BETWEEN CLINICAL ISOLATES BUT NOT ALL COMBINATIONS YIELDED RECOMBINANTS.....	140
7.3. RECOMBINANTS WERE USUALLY MONONUCLEATE AND OFTEN DO NOT COMPLETELY RETAIN THE PARENTAL GENOMES DURING THE SELECTION PROCEDURE.....	150
7.3.1. <i>Recombinants were usually mononucleate with DNA content exceeding that of each parent.....</i>	<i>150</i>
7.3.2. <i>Chromosome loss is unlikely to prevent recovery of recombinants</i>	<i>154</i>
7.3.3. <i>Chromosomes without drug resistance genes were lost frequently during selection</i>	<i>161</i>
8.0. BENEFIT OF SEX IN.....	165
C. <i>ALBICANS</i>	165
8.1. INTRODUCTION.....	166
8.2 IT IS DIFFICULT TO DEMONSTRATE THAT IN <i>C. ALBICANS</i> SEX INCREASES THE CHANCE OF HOMOZYGOUS PARENTS' PASSING ON THEIR GENES TO FUTURE GENERATIONS	167
8.3 POSSESSION OF TWO RESISTANCE MARKERS DOES NOT HAVE AN OBVIOUS NEGATIVE IMPACT ON THE FITNESS OF RECOMBINANTS	181
8.4 GAINING MATING COMPETENCY REDUCES THE CHANCES OF SURVIVAL OF <i>C. ALBICANS</i> ' GENES	184
8.4.1 <i>Loss of MTL heterozygosity reduced the growth rate of parental strains</i>	<i>185</i>
8.4.2 <i>Most of the recombinants grow slower than their heterozygous clinical originals, even after 100 generations.....</i>	<i>192</i>
8.4.3 <i>Introduction of the resistance markers had no significant impact on fitness in 9 of 10 tester strains:</i>	<i>195</i>
8.5. OVERALL, ENGAGING IN SEX PROBABLY REDUCES THE NUMBER OF OFFSPRING PRODUCED BY <i>C. ALBICANS</i>	198
9.0 DISCUSSION	209
9.1 NOT ALL CLINICAL ISOLATES CAN MATE WITH EACH OTHER	211
9.2 MATING BARRIERS BETWEEN CLINICAL ISOLATES	222
9.3 THE FATE OF PARENTAL GENES IN RECOMBINANTS.....	225

9.4. SEX DIMINISHED PARENTS' CHANCES TO PASS ON THEIR GENES TO FUTURE GENERATIONS.	228
9.5. CONCLUSIONS	243
10.0. APPENDICES	245
10.1. APPENDIX 10.1. PLASMID PJK850.....	246
10.2. APPENDIX 10.2. PLASMID PBLUESCRIPTII KS(+)	247
10.3. APPENDIX 10.3. PLASMID PLASMID P3408	248
10.4. APPENDIX 10.4. PLASMID PNZ18.....	249
10.5. APPENDIX 10.5. PLASMID PCAITHE5.....	250
10.6. APPENDIX 10.6. PLASMID P99RLU	251
10.7. APPENDIX 10.7. PLASMID PGEMT-EASY	252
10.8. APPENDIX 10.8. SEQUENCE OF PLASMID PNZ11 (GENBANK: FJ804173.1).....	253
10.9. APPENDIX 10.9. SEQUENCE OF PLASMID PNZ4 (GENBANK: FJ804172.1).....	257
10.10. APPENDIX 10.10. TABLE OF MATING EXPERIMENTS.....	263
10.11. APPENDIX 10.11. TABLE OF FACS ANALYSIS.....	266
10.12. APPENDIX 10.12. RAW DATA OF FACS EXPERIMENTS OF RECOMBINANTS AND THEIR PARENTS.	269
10.13. APPENDIX 10.13. RAW DATA OF ALL GROWTH EXPERIMENTS	269
11.0. REFERENCES	271

LIST OF FIGURES

Figure 1.1. <i>C. albicans</i> is a polymorphic yeast.....	6
Figure 1.2. GPG strains and non-GPG strains.....	9
Figure 1.3. The two-fold cost of sex.	12
Figure 1.4. The <i>S. cerevisiae</i> and <i>C. albicans</i> mating-type loci.	21
Figure 1.5. Mating-type loci of <i>S. cerevisiae</i> on chromosome III.	22
Figure 1.6. Mating in <i>C. albicans</i>	26
Figure 2.1. An example of multiple growth rate determinations at different times for that same strain (W43).....	62
Figure 2.2. Principle of recombinant PCR used to combine two fragments.	75
Figure 3.1. Neighbour joining tree of 266 infection-causing isolates of <i>C. albicans</i> , collected from a variety of types of infections from 11 locations worldwide, between 1984-1991 (Schmid et al., 1999).	95
Figure 3.2. PCR screen for verification of GPG or non-GPG strains.	99
Figure 3.3. PCR screen of <i>MTL</i> alleles for the model strains (refer to Table 3.1)..	101
Figure 3.4. Matrix of 25 possible matings.....	104
Figure 4.1. Principle of the two-marker system for marking parental strains and the generation of recombinant strains.	107
Figure 4.2. Construction of NAT resistance cassette-containing plasmid pNZ11.	108
Figure 4.3. Construction of MPA resistance cassette-containing plasmid pNZ4...	113
Figure 5.1. MPA selection has a high background.	119
Figure 5.2. Intended integration of <i>MPA^r</i> resistance cassette on chromosome 7 by double cross-over.	120
Figure 5.3. Examples of PCR screens for the correct integration of MPA resistance cassette in marked parents.	121
Figure 5.4. Intended integration of the NAT resistance cassette on chromosome 1 by single cross-over (A) or double cross-over integration (B).....	124
Figure 5.5. Examples of PCR screen for the correct insertion of NAT resistance cassette in marked parents (OD8916 α -pNZ11 and W17 α -pNZ11).....	125

Figure 5.6. Southern blot of parental strains containing the MPA resistance marker.	128
Figure 5.7. Southern blot of parental strains containing the NAT resistance marker.	129
Figure 6.1. Overview of the mating procedure and selection of recombinants from three <i>MTLα</i> strains crossed with one <i>MTLα</i> strains.	134
Figure 6.2. MPA/NAT dual selection on MA plates.	137
Figure 6.3. White / opaque cell transition detected on YPD-Phloxine B plates.....	138
Figure 7.1. Outcome of matings between 25 combinations of <i>MTL</i> homozygous derivatives of 10 clinical isolates.	141
Figure 7.2. Efficiency of mating in the 25 mating experiments.	143
Figure 7.3. Mating with universal tester strains to test the mating capability of clinical isolates.	145
Figure 7.4. Alignment of FJ11 α <i>MTLα</i> 1 and SC5314 <i>MTLα</i> 1 (data from Stanford <i>C. albicans</i> database).	146
Figure 7.5. Bar graph showing semi-quantitative mating frequencies of clinical isolates with the universal tester strains.....	149
Figure 7.6. Examples of FACS analyses of parental strains and recombinants with SYTOX staining.....	151
Figure 7.7. Examples of staining the nuclei of parental strains and recombinants with DAPI.	152
Figure 7.8. Presence of parental resistance markers in recombinants when first recovered after the mating procedures and after serial propagation for 100 generations.	158
Figure 7.9. Both <i>MTL</i> alleles are retained in recombinants after 100 generations.	159
Figure 7.10. Relationship between the (average \pm s.d, if more than 1 recombinants were obtained) DNA content of recombinants relative to that of the sum of their both parents and the mating efficiency of each successful mating.	160
Figure 7.11. PCR analysis of retention of resistance cassette-free copies of chromosomes 1 and 7 in the offspring of two matings.....	163
Figure 7.12. PCR analysis of retention of individual copies of chromosome 2 in offspring from the mating of W43 <i>MTLα</i> and W17 <i>MTLα</i>	164

Figure 8.1. Comparison of the average growth rates (\pm std) of the recombinants and the pair of parents from which they were derived, for the 15 successful matings, when they just isolated.....	168
Figure 8.2. Comparison of the average growth rates (\pm std) of the recombinants and the pair of parents from which they were derived, for the 15 successful matings after propagation for 100 generations in YPD medium.....	169
Figure 8.3. Median growth rates of parents and recombinants.....	170
Figure 8.4. DNA content of 28 representative recombinants from the 15 successful matings relative to the average DNA content of their parents before and after 100 generations.	174
Figure 8.5. Relationship between the increase in the growth rate and decrease of the DNA content of recombinants after 100 generations serial transfer in YPD medium.	175
Figure 8.6. Changes in the growth rates of twelve recombinants during serial propagation over 100 generations.	176
Figure 8.7. Simulation of the benefit of sex for individual strain (size of progeny from one cell engaging in sex relative to that of continued clonal reproduction).	179
Figure 8.8. Simulation of the benefit of sex for pairs of strains (size of progeny of two cells engaging in sex relative to that of continued clonal reproduction).	180
Figure 8.9. Growth rates of <i>MTL</i> -heterozygous and <i>MTL</i> -homozygous <i>C. albicans</i> strains.....	186
Figure 8.10. Increase in the growth rate of sorbose selection-derived <i>MTL</i> -homozygous derivatives of clinical isolates with culturing in YPD.	187
Figure 8.11. Growth rates of 9 clinical <i>MTL</i> -heterozygous parental strains and 34 recombinants derivatives before (t_0) and after 100 generations in YPD.	190
Figure 8.12. Comparison of recovery of growth rate in YPD of <i>MTL</i> -homozygous derivatives of W43 and OD8916 derived from YPD and sorbose, respectively, during serial propagation in YPD.....	191
Figure 8.13. Effect of marker cassettes on growth rates of <i>MTL</i> -homozygotes.....	194
Figure 8.14. Simulation of the number of progeny produced by individual cells which became <i>MTL</i> -homozygous at t_0 and the progeny of which mated after 30 generations, (marked by arrow).	200

Figure 8.15. Simulation of the number of progeny produced by pairs of cells which became *MTL*-homozygous at t_0 and the progeny of which mated after 30 generations, (marked by arrow).203

Figure 8.16. Alternative simulation of the number of progeny produced by individual cells which became *MTL*-homozygous at t_0 and the progeny of which mated after 30 generations, (marked by arrow).206

Figure 8.17. Alternative simulation of the number of progeny produced by pairs of cells which became *MTL*-homozygous at t_0 and the progeny of which mated after 30 generations, (marked by arrow).207

LIST OF TABLES

Table 2.1. <i>C. albicans</i> strains used in this study.....	42
Table 2.2. Naturally occurring <i>MTL</i> -homozygous clinical isolates.....	44
Table 2.3. <i>E. coli</i> strains used in this study	45
Table 2.4. Suppliers of Materials and Equipments	46
Table 2.5. Plasmids used in this study	49
Table 2.6. Plasmids developed during this study.....	50
Table 2.7. Primers used in this study	56
Table 3.1. Model strains selection and verification	98
Table 3.2. <i>MTL</i> status of colonies recovered from sorbose plates.....	103
Table 5.1. <i>MTL</i> homozygous derivatives marked with drug resistance cassettes ..	118
Table 8.1. Average growth rates of single marked and double marked <i>MTL</i> homozygous strains when first isolated and after 100 generations of serial propagation	182
Table 10.1. Results of mating experiments	263
Table 10.2. Comparison of DNA content and number of nuclei in parents and recombinants	266

ABBREVIATIONS

Amp	Ampicillin
aa	amino acid
APS	ammonium persulfate
AWCGS	Alan Wilson Centre Genome services
bp	base pair
⁰ C	degree Celsius
<i>C. albicans</i>	<i>Candida albicans</i>
CAIP	Calf intestinal alkaline-phosphate
cDNA	Complementary DNA
Chr (chr)	Chromosome
cm	Centimetre
CSPD	Chloro-5-substituted adamantyl-1,2-dioxetane phosphate
g	gram
DIG	Digoxigenin
DAPI	4', 6'-diamidino-2-phenylindole
DNA	Deoxyribonucleic acid
dATP	2'-deoxyadenosine-5'-triphosphate
dCTP	2'-deoxycytidine-5'-triphosphate
dGTP	2'-deoxyguanosine-5'-triphosphate
dTTP	2'-deoxythymidine-5'-triphosphate
dNTP	Deoxynucleoside triphosphate

DTT	Dithiothreitol
DMSO	Dimethyl sulfoxide
<i>E.coli</i>	<i>Escherichia coli</i>
EDTA	Ethylenediamine tetra-acetic acid
FACS	Fluorescence Activated Cell Sorting
GPG	General purpose genotype
h	hour
IPTG	Isopropyl- γ -D-thiogalactopyranoside
kb	kilobase
L	litre
LB	Luria-Bertaini medium
mg	milligram
μ l	microlitre
M	Molar, moles per litre
ml	millilitre
MPA	mycophenolic acid
MM	Minimal medium
MTL	Mating-type like
NAT	nourseothricin
Non-GPG	non-general purpose genotype
OD	Optical Density
ORF	open reading frame
PAGE	Polyacrylamide gel electrophoresis
pBSKS(+)	pBluescript KS(+)
PCR	Polymerase chain reaction

pH	-Log[H ⁺]
RNase	Ribonuclease
rpm	Revolutions Per Minute
<i>S. cerevisiae</i>	<i>Saccharomyces cerevisiae</i>
SDS	sodium dodecyl sulfate
TAE	Tris/ Acetic acid /EDTA
TBE	Tris/Borate/EDTA
TNE	Tris/NaCl/EDTA
TEMED	N,N,N',N'-Tetramethylethylenediamine
X-gal (BCIG)	bromo-chloro-indolyl-galactopyranoside
YPD	Yeast Extract Peptone Dextrose Medium
w/v	Weight/volume